Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A smarter steroid delivery system shows broad benefits for chronic sinusitis. A new study found that fluticasone delivered via an exhalation device (EDS-FLU) significantly reduced symptoms and improved quality of life in adults with chronic rhinosinusitis — and the benefits held up regardless of whether patients had asthma, environmental allergies, or varying eosinophil levels.
A smarter steroid delivery system shows broad benefits for chronic sinusitis
Chronic rhinosinusitis (CRS) is notoriously tricky to treat because it comes in different inflammatory "flavors." But a new post hoc analysis of two phase 3 trials suggests that fluticasone delivered via an exhalation delivery system (EDS-FLU) works well across the board — regardless of a patient's asthma status, allergy profile, or blood eosinophil count.
The device uses exhaled breath to push the steroid deeper into the nasal passages — reaching areas that standard sprays can't access. Across 547 adults, EDS-FLU produced meaningful reductions in congestion, facial pain, and nasal discharge as early as week 4, with quality-of-life improvements sustained through week 24.
Key Takeaways:
Why it matters: CRS affects millions and is often undertreated due to uncertainty about which patients will respond. These findings suggest clinicians can consider EDS-FLU broadly, without needing to tailor decisions to a patient's inflammatory endotype.
